Compared with the other groups, the EXO‐PD‐L1‐HGF treatment group displayed a significant improvement in neurobehavioral examination, as measured by means of rotarod treadmill testing and beam walking, at 28 d postischemic stroke. The gene discussed is CD274; the disease is Stroke.